Multiple Sclerosis (MS)

MS is a demyelinating disease. This means that the myelin sheath that protects and nerve cells is damaged, impairing the conduction of signals across nerve cells. The cause of MS is not fully known, but it could have something to do with the destruction of the immune system, the body failing to produce myelin cells, genetics, viruses and environmental factors.

Symptoms of MS includes vision problems (occasionally even blindness), fatigue, numbness, tingling, muscle spasms, mobility problems, confusion and problems with thinking & planning, depression and anxiety and pain. Symptoms can build over time in a progressive manner as well as take the form of recurring, isolated attacks. MS is the most common autoimmune disorder affecting the central nervous system (CNS).

Approximately 2.5 million people worldwide suffer from MS, and of those diagnosed with MS, the US makes up around 400,000 of them. Rates of MS are higher farther from the equator. According to Healthline, 200 new cases of MS arise in the US each week. Onset is usually between 20 and 40 years of age, but can arise at any age from 10 years old to 80 years old, with a mean of 32 years old.

Though there is quite a bit of empirical and anecdotal research out there showing that CBD can prove to be helpful for MS, it is THC that has proven usefulness in battling MS, as it helps manage spasticity. There is already a medication in the UK developed for MS using THC, named Sativex. Sativex may also be of use for the neuropathic pain associated with MS. Sativex is produced by GW Pharmaceuticals.

Value of Medical Marijuana

30 out of 4,276 (0.7%) of patients surveyed use medical marijuana for multiple sclerosis. THC may help manage muscle spasms and stiffness, and CBD may be neuroprotective and counteract the development of MS in the first instance. Cannabis can also potentially be used to manage neuropathic pain.

Positives

  • Group 3 Copy
  • Group 3 Copy
  • Group 3 Copy
  • Group 3 Copy
  • Group 3 Copy

Negatives

  • Group 3 Copy 2
  • Group 3 Copy 2

Treatments

Indicas were overwhelmingly favoured by patients with MS, with 40% choosing indica strains. Sativas and hybrids were preferred by 3.33% of patients surveyed. GW Pharma’s Sativex is based on a 1:1 THC:CBD ratio, although our survey only shows 3.33% of patients preferring to use a 1:1 ratio specifically. Still, this doesn’t mean that patients aren’t choosing indica strains with high amounts of CBD in them, perhaps in some cases even surpassing the 1:1 ratio. CBD-rich strains were used by 6.67% of MS patients. Overall, it seems most people with MS go CBD-hunting to an extent, although THC definitely has its place, and indicas aren’t necessarily short on the THC, either.

  • 40%

    Indica

  • 3.33%

    Sativas

  • 3.33%

    Hybrids

78% of people replaced or reduced intake of their normal medications

Know more of our discoveries in our study about Medical Marijuana

Read the study

78% of people replaced or reduced intake of their normal medications

Know more of our discoveries in our study about Medical Marijuana

Read the study

Patients Stories

View all

Relevant Articles

View all